-
Cardiac Care for Female Carriers
While February may be known for Valentine’s Day candy and flowers, it is also American Heart Month! Within the dystrophinopathy community, keeping heart health front and center is especially critical. It is estimated that around 67% of mothers of children with Duchenne muscular dystrophy and nearly 90% of mothers of children with Becker muscular dystrophy…
-
Napa in Newport Returns as a Three-Day Celebration of Napa Wine Benefiting CureDuchenne
Napa’s Finest Come to Newport Beach, Led by Vintner Chair Peter Michael Winery NEWPORT BEACH, California (February 5, 2026) – CureDuchenne, a global leader in accelerating research and care for Duchenne muscular dystrophy, has announced that its annual Napa in Newport event will debut as an elevated weekend-long experience, showcasing the best of Napa Valley in coastal luxury. Taking place March…
-
CureDuchenne Announces Educational Events for Duchenne and Becker Families and Caregivers
Free nationwide events deliver expert guidance and meaningful connections for families impacted by Duchenne and Becker muscular dystrophy NEWPORT BEACH, Calif., February 4, 2025 – CureDuchenne, a global leader in advancing research and improving patient care for individuals with Duchenne and Becker muscular dystrophy, today announced the 2026 lineup of CureDuchenne CARES events, designed to deliver the latest treatment insights,…
-
Our 2026 Advocacy Agenda
After a year of twists and turns in 2025, MDA and its advocates are even more motivated to raise their voices and create change for the neuromuscular community. Check out the roadmap for the next 12 months and learn how you can make an impact in 2026. Celebrating early victories on previous priorities 2026 got…
-
FDA fast tracks Dyscorban for treating heart problems in Duchenne
The U.S. Food and Drug Administration (FDA) has granted fast track designation to Dyscorban (ifetroban), Cumberland Pharmaceuticals’ treatment candidate for heart problems in Duchenne muscular dystrophy (DMD). Dyscorban has been tested in the Phase 2 FIGHT DMD trial (NCT03340675), with data showing that it improved heart function and reduced markers of heart damage in individuals with…
-
Terapia Génica ELEVIDYS
Terapia Génica ELEVIDYS: Actualización Comunitaria Más Reciente con Sarepta Therapeutics Watch HERE The post Terapia Génica ELEVIDYS appeared first on CureDuchenne.
-
MDA Ambassador Guest Blog: Pursuing My Dreams While Living with a Rare Disease
Gabrielle Runyon is a graduate student in the Master’s Counseling Program at the illustrious Tennessee State University. She is from Louisville, Kentucky. Gabrielle was diagnosed with spinal muscular atrophy (SMA) when she was one year old. Her fun fact is that she can play three instruments. Living with a rare disease, I learned early on…
-
My emotions blurred as I watched my play from ‘The Other Side’
In my previous column, I shared my experience of stepping away from performing in my own play, “The Other Side,” and trusting that the work could continue without me at its center. This column picks up where the last left off: the moment the play met its audience, and I found myself watching from an…
-
MDA-led project to map how human muscles repair themselves
A research collaboration led by the Muscular Dystrophy Association (MDA) aims to create a molecular map of human muscle regeneration, a project that could accelerate the development of muscle repair-based therapies for people with muscular dystrophy (MD). Abigail Mackey, PhD, a professor of muscle physiology and regeneration at Copenhagen University Hospital, will lead the project,…
-
Conoce a Rosalia Sandoval Garcia
Rosalia es una orgullosa mamá de Joe (8), quien vive con Duchenne, y de Sophia (6). Ella misma vive con distrofinopatía, lo que hace que esta misión sea especialmente cercana a su corazón. Con 13 años de experiencia como terapeuta del habla bilingüe en el área de Austin, Texas, Rosalia siente una gran pasión por…
